Extensive Intraductal Component in Breast Cancer: What Role in Disease-Free Survival?
暂无分享,去创建一个
M. Truffi | F. Corsi | L. Sorrentino | M. Sevieri | S. Albasini | Laura Villani | L. Villani | Simone Ciciriello
[1] T. Kawahara,et al. Using Propensity Scores for Causal Inference: Pitfalls and Tips , 2021, Journal of epidemiology.
[2] Y. Xiong,et al. Tumor size and focality in breast carcinoma: Analysis of concordance between radiological imaging modalities and pathological examination at a cancer center. , 2020, Annals of diagnostic pathology.
[3] T. Ohta,et al. Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast , 2020, medRxiv.
[4] Seigo Nakamura,et al. Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges. , 2020, Pharmacogenomics.
[5] H. Gómez,et al. Multigene assays in early breast cancer: Insights from recent phase 3 studies. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[6] M. Truffi,et al. Radio‐guided and clip‐guided preoperative localization for malignant microcalcifications offer similar performances in breast‐conserving surgery , 2019, The breast journal.
[7] Abhijit A. Patel,et al. Overall survival is improved when DCIS accompanies invasive breast cancer , 2019, Scientific Reports.
[8] S. Mazzucchelli,et al. Radio‐guided vs clip‐guided localization of nonpalpable mass‐like lesions of the breast from a screened population: A propensity score‐matched study , 2019, Journal of surgical oncology.
[9] H. Kim,et al. Mammography, US, and MRI to Assess Outcomes of Invasive Breast Cancer with Extensive Intraductal Component: A Matched Cohort Study. , 2019, Radiology.
[10] J. Seco Calvo,et al. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study. , 2019, International journal of surgery.
[11] J. Landercasper,et al. Update of the American Society of Breast Surgeons Toolbox to address the lumpectomy reoperation epidemic. , 2018, Gland surgery.
[12] San-Gang Wu,et al. Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis , 2018, Cancer management and research.
[13] A. Sieuwerts,et al. TUMORIGENESIS AND NEOPLASTIC PROGRESSION Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer , 2022 .
[14] M. Bonzini,et al. Cavity Shaving Reduces Involved Margins and Reinterventions Without Increasing Costs in Breast-Conserving Surgery: A Propensity Score-Matched Study , 2017, Annals of Surgical Oncology.
[15] M. Bonzini,et al. Localization of nonpalpable breast lesions with sonographically visible clip: optimizing tailored resection and clear margins. , 2015, American journal of surgery.
[16] Tae-Min Kim,et al. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer , 2015, Oncotarget.
[17] I. Zapardiel,et al. Influence of the in situ component in 389 infiltrating ductal breast carcinomas , 2013, Breast Cancer.
[18] A. Gavin,et al. Increased diagnosis and detection rates of carcinoma in situ of the breast , 2012, Breast Cancer Research and Treatment.
[19] J. Reis-Filho,et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection , 2012, The Journal of pathology.
[20] T. Yau,et al. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer , 2010, British Journal of Cancer.
[21] K. McMasters,et al. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis? , 2009, Surgery.
[22] J. Coebergh,et al. Screening caused rising incidence rates of ductal carcinoma in situ of the breast , 2009, Breast Cancer Research and Treatment.
[23] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[24] Kornelia Polyak,et al. Ductal Carcinoma in Situ of the Breast , 2004, Strahlentherapie und Onkologie.
[25] H. Kooy,et al. Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[26] J. Jacquemier,et al. An assessment of extensive intraductal component as a risk factor for local recurrence after breast-conserving therapy. , 1990, British Journal of Cancer.
[27] S. Schnitt,et al. Pathologic predictors of early local recurrence in stage I and II breast cancer treated by primary radiation therapy , 1984, Cancer.
[28] Virginia Espina,et al. What is the malignant nature of human ductal carcinoma in situ? , 2011, Nature Reviews Cancer.